Tatva Chintan Pharma Chem shareholding pattern

TATVA

1192.9

30.60 (-2.50%)
Last updated on 2 Mar, 2026 | 09:45 IST
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Tatva Chintan Pharma Chem Shareholding Pattern

  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

72.02%

Mutual Fund

3.25%

Insurance

0%

Foreign Institutional Investors

4.17%

Domestic Institutional Investors

0.08%

Retail

20.48%

Others

0%

Total Promoters
MAR '25
72.02%
JUN '25
72.02%
SEP '25
72.02%
DEC '25
72.02%

Summary

For Year 2025-26, Tatva Chintan Pharma Chem reports the following shareholding: Total Promoters at 72.02%, Mutual Fund at 3.25%, Insurance at 0%, Foreign Institutional Investors at 4.17%, Domestic Institutional Investors at 0.08%, and Retail at 20.48%. This breakdown provides a quick snapshot of ownership distribution for Tatva Chintan Pharma Chem in 2025-26.

Tatva Chintan Pharma Chem FAQs

As of 03-2026, the promoter shareholding in Tatva Chintan Pharma Chem stands at 72.02% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Tatva Chintan Pharma Chem is 4.17% and 0.08% respectively.

The retail shareholding of the Tatva Chintan Pharma Chem is 20.48%.

Changes in shareholding patterns of Tatva Chintan Pharma Chem can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Tatva Chintan Pharma Chem are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost